Armistice Capital’s Neurocrine Biosciences NBIX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$95.4M	Sell	724,000 -96,240	-12%	-$12.8M	3.15%	9
2025 Q4	$116M	Buy	820,240 +123,218	+18%	+$17.9M	2.85%	8
2025 Q3	$97.8M	Buy	697,022 +20,998	+3%	+$2.85M	3.07%	7
2025 Q2	$85M	Sell	676,024 -324,166	-32%	-$37.2M	3.22%	7
2025 Q1	$111M	Buy	1,000,190 +108,190	+12%	+$13.7M	2.96%	6
2024 Q4	$122M	Buy	892,000 +710,619	+392%	+$87.9M	2.83%	7
2024 Q3	$20.9M	Sell	181,381 -797,107	-81%	-$109M	0.55%	57
2024 Q2	$135M	Sell	978,488 -45,251	-4%	-$6.21M	3.52%	5
2024 Q1	$141M	Sell	1,023,739 -24,261	-2%	-$3.31M	3.76%	4
2023 Q4	$138M	Sell	1,048,000 -168,365	-14%	-$19.4M	3.67%	4
2023 Q3	$137M	Sell	1,216,365 -433,635	-26%	-$45.7M	4.07%	5
2023 Q2	$156M	Buy	1,650,000 +58,000	+4%	+$5.67M	3.91%	3
2023 Q1	$161M	Buy	1,592,000 +692,000	+77%	+$72M	3.75%	3
2022 Q4	$107M	Sell	900,000 -424,000	-32%	-$49.7M	2.89%	10
2022 Q3	$141M	Hold	1,324,000	–	–	3.54%	7
2022 Q2	$129K	Buy	1,324,000 +674,000	+104%	+$62.2M	2.25%	7
2022 Q1	$60.9M	Buy	+650,000	New	+$55.1M	1.73%	25